TAK-994 is an oral, selective OX2R agonist?developed by Takeda for the treatment of narcolepsy type 1 (with?cataplexy) and type 2 (without cataplexy). The molecule follows Takedas previous clinical molecule,?TAK-925?(danavorexton), which was the first O
CAS Number:
[2861934-86-1]
* VAT and and shipping costs not included. Errors and price changes excepted
